XOMA Corp
NASDAQ:XOMA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
14.79
33.88
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
XOMA Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | US |
Market Cap | 398.3m USD |
Net Margin |
-184%
|
Country | FR |
Market Cap | 6T USD |
Net Margin |
-21 040%
|
Country | US |
Market Cap | 320.1B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 147.4B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 119.4B USD |
Net Margin |
-5%
|
Country | US |
Market Cap | 113.8B USD |
Net Margin |
0%
|
Country | US |
Market Cap | 94.1B EUR |
Net Margin |
-392%
|
Country | AU |
Market Cap | 135.4B AUD |
Net Margin |
18%
|
Country | US |
Market Cap | 82.6B USD |
Net Margin |
34%
|
Country | US |
Market Cap | 39.3B EUR |
Net Margin |
-33%
|
Country | NL |
Market Cap | 34.3B EUR |
Net Margin |
-14%
|
XOMA Corp
Glance View
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on XOMA Corp's most recent financial statements, the company has Net Margin of -183.6%.